SciClone begins a Phase II trial to evaluate how a new drug designed to stimulate the immune system fares against Hepatitis C.
SciClone starts hepatitis C drug trial
Wednesday, October 21, 2009
SciClone Pharmaceuticals Inc. enrolled the first patient in a mid-stage test of a hepatitis C treatment.
Foster City-based SciClone (NASDAQ: SCLN) signed up the patient in Atlanta to test SCV-07, a small molecule that stimulates the immune system. In this Phase II trial it’s being tested alone or in combination with ribavirin, another drug.
Read the entire article:
http://sanfrancisco.bizjournals.com/sanfrancisco/stories/2009/10/19/daily47.html